# Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

> **NCT04389177** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Stage III

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]

## Key facts

- **NCT ID:** NCT04389177
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-08
- **Primary completion:** 2022-02-17
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389177, "Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04389177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*